event earn growth look
catalyst
action revis forecast nippon shinyaku rais target
price potenti return maintain
invest overview share price movement remain close entwin
pulmonari arteri hypertens pah treatment uptravi progress
develop duchenn muscular dystrophi dmd
expect earn driven domest sale uptravi
royalti payment johnson johnson us nippon shinyaku
tend issu conserv guidanc think earn continu trend
project level expect reced amid
increas attent paid us rival sarepta gene therapi dmd
like subject renew focu compani plan
file regulatori approv japan us around septemb
think approv file made us nippon
shinyaku step construct us sale network firm plan
expans eu expect share price gain momentum
catalysts/risk focu news concern simultan file
approv japan us result triton studi
investig uptravi combin two drug macitentan
tadalafil due favor could lead greater
uptak uptravi risk includ tardi file approv
delay develop licens new drug includ dmd treatment
follow
valuat target price base ep
previous price-to-earnings use bloomberg consensu
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price apr upsid rate outperform target price analyst fumiyoshi sakai
profit tax
issuanc retir stock
net chang cash
number share mn
profit tax
urinari disord caus bph
cancer chronic pain
dev
dev
royalti licens
compani mention price
